TREM2 and neoplasm: Notably, TREM2 knockout combined with the galectin-3 inhibitor GB1107 substantially inhibited the immunosuppressive effect of M2-TAMs and enhanced T/NK cell-mediated anti-tumor effects, improving the efficacy of lung cancer therapy (Fig. 8G).